MannKind Q1 revenue rises 15% but swings to net loss

MannKind

06/05/2026 21:12

Overview

US biopharma firm's Q1 revenue rose 15% yr/yr, driven by royalties and Furoscix sales

Company posted Q1 net loss of $16.6 mln, compared to profit in prior year

Operating expenses rose sharply due to Furoscix acquisition and expanded commercial activities

Outlook

Company expects Afrezza pediatric indication FDA decision by May 29, 2026

Company anticipates Furoscix ReadyFlow Autoinjector FDA decision by July 26, 2026

MannKind expects first patient enrolled in nintedanib DPI Phase 2 trial in Q2 2026

Result Drivers

FUROSCIX SALES - Addition of Furoscix sales following scPharma acquisition was main driver of commercial product revenue growth

HIGHER ROYALTIES - Increased royalties from United Therapeutics' Tyvaso DPI contributed to revenue growth

LOWER COLLABORATION REVENUE - Revenue from collaborations and services declined due to fewer units sold to United Therapeutics

Company press release: ID:nGNX18PlT2

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.05
Q1 Net Income
-$16.62 mln
Q1 Basic EPS
-$0.05
Q1 Operating Income
-$1.67 mln
Q1 Pretax Profit
-$16.37 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MannKind Corp is $7.50, about 162.2% above its May 5 closing price of $2.86

The stock recently traded at 74 times the next 12-month earnings vs. a P/E of 68 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)